Abstract: A new oral pharmaceutical dosage form comprising a core material that contains a proton pump inhibitor, one or more alkaline reacting compounds and optionally pharmaceutical excipients having a water soluble separating layer and an enteric coating layer. The core material as such is alkaline reacting and the separating layer between the alkaline reacting core material and the enteric coating layer is formed in situ as a water soluble salt between the alkaline reacting compound(s) and the enteric coating polymer. The invention also describes a new efficient process for the manufacture of such a dosage form comprising two functionally different layers in one manufacturing step, and its use in medicine.

Abstract: To provide a medicament that can be used as a drug for the effective treatment of gastric ulcers, duodenal ulcers and like diseases of the digestive tract. The medicament comprises a combination of at least one agent selected from the group consisting of histamine H.sub.2 receptor antagonists and proton pump inhibitors, and a digestive enzyme.

Abstract: Tissue-destructive conditions related to excess proteinase activity in a biological system are treated or prevented by administering to the system a composition which combines a tetracycline and a bisphosphonate in synergistic proteinase inhibiting amounts.

Abstract: A method for treating various diseases with a dried total extract of Rosmarinus officinalis. The dried total extract is obtained by macerating Rosmarinus officinalis leaves in hydrated ethyl alcohol for a period of 10-20 days, filtering, and drying. The dried extract has been demonstrated to be highly effective in treating patients suffering from varicose and neurotrophic ulcers, inner ear disorders, and hemorrhoids, when administered orally. The dried extract has low acute and chronic toxicity in both animals and humans. There are no side effects to the treatment.

Abstract: Disclosed are compositions comprising non-steroid anti-inflammatory drugs (NSAID'S) complexed with zwitterionic, neutral phospholipids, or both, having reduced gastrointestinal irritating effects and enhanced antipyretic, analgesic, and antiinflammatory activity. Also disclosed are improved methods of using the complexes for treating fever, inflammation, and preventing platelet aggregation. In some embodiments, the anti-pyretic activity of sub-therapeutically used amounts of NSAID's are enhanced to elicit anti-pyretic activity in vivo when associated (noncovalently) with zwitterionic phospholipids, such as dipalmitoyl phosphatidyl choline. Methods and compositions useful for enhancing the therapeutic activity of non-steroidal anti-inflammatory agents in the presence of anti-secretory agents are also discussed.

Abstract: Use of compounds of formula (I), wherein R has various significances, in free base form or in pharmaceutically acceptable salt form, as agents against H. pylori infection and associated diseases.

Abstract: The present invention relates to the use of non-bacterial plasminogen activators in the manufacture of a topical medical preparation for the treatment of slow- or non-healing wounds. In addition, the present invention relates to a composition comprising a physiologically acceptable carrier and an effective amount of a non-bacterial plasminogen activator, with the exclusion of t-PA. Finally, the present invention is directed to a method of treatment of slow- or non-healing wounds comprising the topical application of a non-bacterial plasminogen activator to the site of a wound.

Abstract: Aminophenol derivatives represented by the following formula (1): ##STR1## wherein X is O or S; A is alkylene, R.sup.1 is phenyl, etc., R.sup.2 and R.sup.3 are H or alkyl; R.sup.4 is substituted carbamoylalkyl, etc.; R.sup.5 is substituted amino, etc.; their salts, and optical isomers of the derivatives and salts. Also disclosed are gastrin receptor antagonists, cholecystokinin receptor antagonists, and medicines for digestive diseases. The compounds have strong binding inhibition against gastrin receptor or CCK-A receptor and also they have higher selectivity to either group of CCK-A receptor or gastrin receptor, and therefore, the compounds are useful for preventing and treating gastrointestinal diseases including peptic ulcers as well as central nervous system diseases.

Abstract: Calcium carbonate liquid antacid compositions containing one or more pH adjusting agents to maintain the pH above 9.0, preferably above 9.5. The resultant antacid liquid possesses superior resistance to microbial attack and enhanced taste properties.

Abstract: The present invention relates to a hemostatic composition comprising at least 0.1 NIH U/ml of thrombin, about 0.01 mU/ml of casein kinase II, and from 10 ng/ml to 100 ng/ml of sphingosine or a sphingosine derivative. The composition is effective in treating patients suffering from hemophilia, ulcers, or microbial infections. In addition, the composition is effective in reducing clotting time during the surgical procedure of suturing blood vessels.

Abstract: The invention relates to active substance combinations which consist of at least one polypeptide with the biological action of fibroblast growth factors and of at least one cationic polyelectrolyte. These combinations permit improved dosage of the FGF activity. The invention also relates to a method of treating wounds, burns, skin ulcers, diabetic gangrene, mucosal ulcers and lesions, skin donation and transplantation sites, or surgical wounds by administering a peptide having FGF activity with an amount of cationic polyelectrolyte which is effective to decrease non-specific binding of the peptide having FGF activity.

Abstract: A method for treating photodermatitis, thermal burn, decubitus ulcer, or herpes zoster by topically applying a composition comprising a water soluble vinyl polymer gel or lotion comprising 1H-imidazole-4-ethanamine, phosphate uniformly mixed therewith to the affected areas.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: Medical materials for use in treating maladies in living beings, such as ulcers and other conditions of the digestive tract. In one form, a container is provided for a medication which container also contains an adhesive material which is operatively released from the container or exposed at the surface thereof upon biodegradation or dissolution of a protective coating or wall portion of the container under the effects of fluid in the digestive tract in which the container is exposed, such as by swallowing, to permit such adhesive to temporarily bond and retain the container at a select location in the digestive tract so that it may slowly release its contents thereafter to a select portion of the digestive tract. In another form, a multitude of microcapsules, each containing a small quantity of medication, is mixed with an adhesive material, such as a sulcralfate other material which may be swallowed as a tablet or dissolved in a liquid such as water.

Abstract: This invention is directed to methods of administering physiologically stable and safe compositions of butyric acid salts and derivatives to a patient for the purpose of wound healing.

Abstract: Use of at least one polymer or one biopolymer, called HBGFPPs, specifically protecting the growth factors of families of FGFs and beta TGFs from tryptic degradation and not significantly inhibiting coagulation, in the manufacture of a drug for the treatment of lesions of the digestive tract and of primary or secondary derived tissues of the endoderm and the mesoderm.

Abstract: Complexes of bismuth, e.g. bismuth salts, and polyacrylate, e.g. carbomer, are discloses which may be incorporated into pharmaceutical compositions for oral, oral delayed-release, and rectal administration. The complexes may be combined with an antibiotic, such as tetracycline, and an antiprotozoal agent, e.g. Metronidazole, for use in the treatment of Helicobacter pylori infection. The treatment of inflammatory bowel disease using bismuth/polyacrylate complexes, or other bismuth preparations, is also described.

Abstract: Methods and compositions are provided for prophylactic and antibacterial therapy for Helicobacter, particularly for Helicobacter pylori, infection of humans. The immunogenic composition of the invention is composed of a plurality of multimeric complexes, each complex being composed of recombinant, enzymatically inactive Helicobacter pylori urease. Each multimeric complex is composed of six Urease A subunits and six Urease B subunits. Alternatively, the composition is composed of a mixture of multimeric complexes, wherein each multimeric complex in the mixture is composed of six Urease A subunits and six Urease B subunits or four Urease A subunits and four Urease B subunits.

Abstract: A new pharmaceutical multiple unit tableted dosage form containing omeprazole or one of its single enantiomers or an alkaline salt of omeprazole or one of its single enantiomers, a method for the manufacture of such a formulation, and the use of such a formulation in medicine.

Abstract: Anti-ulcer compositions are disclosed having therapeutic agents dispersed in a soluble matrix formed by melt spinning the therapeutic agent with a carrier and hydrogel. Methods of treating mucosal ulcer-bearing tissue and preparing the matrix are also disclosed. One embodiment includes use of gastric irritating bio-affecting agents in which case the composition is preventative as well as therapeutic.

Abstract: Cross-linked controlled density polyamines which are water-insoluble and swell at pH values up to about 8 are shown. These polyamines are useful in site-specific drug delivery systems.

Abstract: A pharmaceutical dispensing container which holds multiple dosage units for aiding in the compliance in the eradication/treatment for Helicobater pylori and subsequent/related gastric maladies in relation to said bacterial infection using a repetative dosage regimen for a treatment period of sufficient duration to mitigate said bacterial infection formatted in such a way to gain optimal ease of compliance resulting in improved outcome of treatment. Dosage units may be antibiotic, anti microbial, or symtomatic relief agents in any combination.

Abstract: The present invention relates to a method treating or preventing disorders caused by a spiral urease-positive gram-negative bacterium such as Helicobacter pylori in mammals, including humans, using compounds that are substance P receptor antagonists and, specifically, using certain quinuclidine derivatives, piperidine derivatives, pyrrolidine derivatives, azanorbornane derivatives, ethylene diamine derivatives and related compounds.

Abstract: The subject invention encompasses methods for prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria comprising administering to the subject bismuth and one or more antimicrobials. The subject invention also encompasses compositions comprising bismuth and one or more antimicrobials for the prevention and treatment of a human or lower animal subject having a gastrointestinal disorder caused or mediated by algae and/or cyanobacteria.

Abstract: 2,5-Diaryl tetrahydrofurans, 2,5-diaryl tetrahydrothiophenes, 1,3-diaryl cyclopentanes are disclosed that reduce the chemotaxis and respiratory burst leading to the formation of damaging oxygen radicals of polymorphonuclear leukocytes during an inflammatory or immune response. The compounds exhibit this biological activity by acting as PAF receptor antagonists, by inhibiting the enzyme 5-lipoxygenase, or by exhibiting dual activity, i.e., by acting as both a PAF receptor antagonist and inhibitor of 5-lipoxygenase. Also disclosed is a method to treat disorders mediated by PAF and/or leukotrienes that includes administering an effective amount of one or more of the above-identified compounds or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, to a patient in need of such therapy.

Abstract: The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid skin changes. In particular, it should be suitable for functioning as an effective therapeutic agent for the treatment of herpes simplex without significant side effects.The phytotherapeutic agent consists of an extract of components extractable from sage, (Salvia officinalis), ribwort plantain (Plantago lanceolata), greater plantain (Plantago major) and mistletoe (Viscum album).

Abstract: The present invention relates to the surprising and unexpected discovery that a simple alpha hydroxy organic acid, for example, lactic acid, glycolic acid or any of their pharmaceutically compatible salts, may be used in a therapy for treating aphthous ulcers, including canker sores in humans. The therapeutic method according to the present invention comprises exposing tissue suffering from an outbreak of aphthous ulcers to an effective amount of an alpha hydroxy organic acid.

Abstract: Ground germinated rice or an extract of polished rice or germinated rice are effective in preventing or treating ulcers.

Abstract: A method of treating a mammal afflicted with a disorder associated with the Na.sup.+ -independent Cl.sup.- /HCO.sub.3 - exchanger comprising the step of administering a compound selected from those of formula (I): ##STR1## in which R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9, R.sub.10, R.sub.11 and n are as defined in the description, which is effective for alleviating the said disorder.

Abstract: The present invention relates to an improved test composition for the diagnosis of gastric ulcers, duodenal ulcers, gastritis, gastric lymphoma and gastric carcinoma by the detection of the bacteria Helicobacter pylori and the enzyme catalase associated with such conditions. The new test composition differs from the prior art agar compositions in being an aqueous solution containing hydrogen peroxide, urea, monobasic sodium phosphate and bromthymol blue as an indicator, and in being far more rapid than the prior art test compositions.

Abstract: Method of treating venous insufficiency and venous ulcers by administering to a patient in need thereof an effective amount of sulphasalazine or 5-aminosalicylic acid.

Abstract: An external skin treatment agent composition containing an active ingredient comprising a prostacyclin, and/or its optical isomer, having the formula (I): ##STR1## (wherein, R.sup.1 is a hydrogen atom, a straight chain or branched alkyl group of C.sub.1 to C.sub.10, or one equivalent of a cation, R.sup.2 is a substitutable C.sub.1 to C.sub.10 straight chain or branched alkyl group or substitutable C.sub.1 to C.sub.10 straight chain or branched alkenyl group or alkinyl group, R.sup.3 is a straight chain alkyl group of C.sub.1 to C.sub.5, and R.sup.4 and R.sup.5 are independently a hydroxyl group or formula: ##STR2## (where, R.sup.6 is a C.sub.1 to C.sub.5 straight chain or branched alkyl group)) and a carrier.

Abstract: Anti-ulcer compositions are disclosed having therapeutic agents dispersed in a soluble matrix formed by melt spinning the therapeutic agent with a carrier and hydrogel. Methods of treating ulcer-bearing tissue and preparing the matrix are also disclosed. One embodiment includes use of gastric irritating bio-affecting agents in which case the composition is preventative as well as therapeutic.

Abstract: The invention relates to pharmaceutical compositions in the form of pleasant-tasting chewable tablets or chewable coated tablets which, besides the pharmaceutically active ingredient sucralfate, essentially contain at least one rapidly swellable physiologically acceptable gel former plus sugars or sugar substitutes.

Abstract: An oral pharmaceutical composition is described for targeted slow release in the treatment of inflammatory bowel diseases. Also described are pharmaceutical compositions for peroral treatment targeted to different areas of the intestinal tract afflicted by ulcerative colitis and certain aspects of Crohn's disease.

Abstract: The pharmaceutical composition of the invention, which comprises a benzimidazole compound of the formula ##STR1## wherein R.sup.1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl, R.sup.2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl, R.sup.3 and R.sup.5 are the same or different and each is hydrogen, alkyl, alkoxy or alkoxyalkoxy, R.sup.4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy, and m is an integer of 0 through 4, and a basic inorganic salt stabilizing agent, is physically stable. Magnesium and calcium basic inorganic salt stabilizing agents are particularly useful.

Abstract: Disclosed herein is a novel fraction comprising a mixture of boswellic acids, wherein the fraction exhibits anti-inflammatory and antiulcerogenic activities. Also disclosed is a novel boswellic acid compound exhibiting anti-inflammatory, antiathritic and antiulcerogenic activities. Also disclosed is a process for isolating a boswellic acid fraction and individual boswellic acids therefrom.

Abstract: Anti-ulcer compositions are disclosed having therapeutic agents dispersed in a soluble matrix formed by melt spinning the therapeutic agent with a carrier and hydrogel. Methods of treating ulcer-bearing tissue and preparing the matrix are also disclosed. One embodiment includes use of gastric irritating bio-affecting agents in which case the composition is preventative as well as therapeutic.

Abstract: A composition for treating and/or inhibiting gastric and duodenal ulcers, comprising an oligosaccharide selected from the group consisting of Formula I ##STR1## or a mixture thereof; wherein:X is independently OH or NHAc;Y is independently H, or an amino acid or a peptide of 2-100, preferably 2-20, amino acids; andW, W', and W" are each independently H or ##STR2## where Z is independently H or a pharmaceutically acceptable cation; and P is independently H or ##STR3## where Z is defined as above; wherein at least one of W, W' or W" is an .alpha.-N-acetylneuraminic acid moiety, andwherein W' and W" are not simultaneously .alpha.-N-acetylneuraminic acid moietywith the proviso that the compound of Formula II is not NAN .alpha.(2.fwdarw.3)Gal .beta.1-4 Glu or NAN .alpha.(2.fwdarw.6)Gal .beta.1-4 Glu; and a kit for detecting the presence of Helicobacter pylori comprising at least one compound of the Formula I or II, are described.

Abstract: The present invention is directed to a method for the treatment of Helicobacter pylori infection wherein a composition containing protease and an antibacterial agent as active ingredients, which can remove Helicobacter pylori from a stomach at high probability without causing side effects or the occurrence of resistant bacteria, and which can treat and prevent peptic ulcer caused by Helicobacter pylori infection and can prevent the recurrence of peptic ulcer is employed.

Abstract: Sustained release oral drug dosage forms that comprise a tablet or capsule containing a plurality of particles of a solid-state drug dispersed in alkyl cellulose such as hydroxyethylcellulose or hydroxypropylcellulose. Once ingested the tablet or capsule disintegrates to disperse the particles into the stomach where they imbibe water to cause them to swell and also to become slippery, thus enhancing their retention in the stomach. Imbibed water from the gastric fluid dissolves the drug entrapped in the particles and the resulting solution diffuses from the dispersed particles, assuring that no solid drug, which with some drugs is more irritating, contacts the mucosal tissue. A number of embodiments of the dosage form utilizing different drugs are exemplified and the benefits are explained. Aspirin is one example.

Abstract: The present invention provides a method for aiding healing or preventing the onset of intestinal wounds or ulcers in a patient. In addition, the present invention provides a method for reducing, or preventing, the gastrointestinal side effects associated with the administration of a nonsteroidal anti-inflammatory drug. Pursuant to the present invention, the composition includes a protein source, a carbohydrate source, a fat source, and a specialized vitamin and mineral profile.

Abstract: A method of treating a PAF-mediated pathology or for treating or preventing psoriasis, nephritis, asthma, inflammation or shock by administering an effective amount of a PAF antagonist of the formula ##STR1## wherein R.sup.1 and R.sup.2 are each --R.sup.5, --CH.dbd.CH--R.sup.5 or --C.tbd.C--R.sup.5 ; R.sup.5 is an unsubstituted or substituted C.sub.6 -C.sub.14 carbocyclic aryl of an aromatic heterocyclic having from 5 to 14 ring atoms, of which from 1 to 5 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur, the heterocyclic group being unsubstituted or substituted; R.sup.3 is hydrogen, a C.sub.1 -C.sub.6 alkyl, cyano, or --R.sup.5 ; X is oxygen or sulfur; A is a 1,4-piperazin-1,4-diyl or a 1,4-homopiperazin-1,4-diyl; B is a C.sub.1 -C.sub.6 alkylene, carbonyl, thiocarbonyl, sulfinyl or sulfonyl; and R.sup.4 is an unsubstituted or substituted phenyl group.

Abstract: Complexes of deprotonated hyaluronic acid with 3d metal ions of the 4th period of the Periodic Table and compositions containing these complexes as active ingredients or carriers. A process for the preparation of the complexes and compositions (pharmaceutical and cosmetic compositions) containing these complexes as active ingredients are disclosed in which zinc hyaluronate is preferably used as active ingredient.

Abstract: A preparation containing an aluminum salt of a sucrose sulfate ester (sucralfate) and polyethylene glycol, and a process for preparation of the same are disclosed. Sucralfate is extensively used as a curative for digestive ulcers and has the capability of protecting the substrate protein. Sucralfate is mixed with polyethylene glycol to provide it with improved disintegrability and dispersibility and this renders sucralfate more useful as a medicine.

Abstract: A complex material of a hydrophilic polymer-silicate mineral comprising a carboxyl group containing hydrophilic polymer and a water swellable silicate mineral, and having a new absorption spectrum not existing in both starting materials in the IR-ray absorption spectrum within the range of 1000 to 1300 cm.sup.-1, and pharmaceutical and cosmetic compositions comprising same.

Abstract: The present invention relates to the use of 1-{4-[4-aryl(or heteroaryl)-1-piperazinyl]butyl}-1H-azole derivatives and of their physiologically acceptable salts for the manufacture of medicaments intended for the treatment of disorders associated with gastric secretion.

Abstract: A novel pharmaceutical use of a dihydropyridine derivative of the formula (I) ##STR1## wherein R.sub.1, R.sub.2 and R.sub.3 are the same or different and each is an alkyl or the like; R.sub.4 is a hydrogen atom or the like; R.sub.5 is nitro, a halogenated alkyl, cyano or the like; X is a vinylene or an azomethine; A is an alkylene; and B is --N(R.sub.6) (R.sub.7) or a group of the formula ##STR2## wherein R.sub.6 and R.sub.7 are the same or different and each is an alkyl, an aralkyl, an aryl or the like; R.sub.8 and Ar are aryl or the like; and n is 0, 1 or 2, or an acid addition salt thereof for promoting PGI.sub.2 production, and for the treatment and prevention of hyperlipemia, arteriosclerosis and cerebral diseases.

Abstract: The invention relates to novel, pharmaceutically active trisubstituted cycloalkane derivatives, a process for the preparation thereof and pharmaceutical compositions comprising the same. The invention also encompasses the use of the said cycloalkane derivatives for the treatment of diseases and for the preparation of pharmaceutical compositions suitable for the treatment of diseases.The compounds according to the invention are characterized by the general formula (I), ##STR1## wherein R represents hydrogen, C.sub.1-4 alkyl or hydroxyl,R.sup.1 stands for C.sub.1-12 alkyl,R.sup.2 and R.sup.3 each represents hydrogen, C.sub.1-12 alkyl or C.sub.2-12 alkenyl, orR.sup.2 and R.sup.3 together with the adjacent nitrogen atom form a 4- to 7-membered ring optionally comprising an oxygen, sulfur or a further nitrogen atom, which latter may carry a phenyl, benzyl or C.sub.1-4 alkyl substituent,R.sup.4 and R.sup.5 each stands for hydrogen, halogen or C.sub.

Abstract: The present invention relates to the surprising and unexpected discovery that a simple alpha hydroxy organic acid, for example, lactic acid, glycolic acid or any of their pharmaceutically compatible salts, may be used in a therapy for treating aphthous ulcers, including canker sores in humans. The therapeutic method according to the present invention comprises exposing tissue suffering from an outbreak of aphthous ulcers to an effective amount of an alpha hydroxy organic acid.